4 Notable Health Tech Funding Announcements in August
Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds.
First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations.
AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation
If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes
Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up
A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care.
SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven
Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S.